Company registration number 06521889 (England and Wales)
THE HIGHLANDS PHARMACY LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024
PAGES FOR FILING WITH REGISTRAR
THE HIGHLANDS PHARMACY LIMITED
CONTENTS
Page
Balance sheet
1
Statement of changes in equity
2
Notes to the financial statements
3 - 7
THE HIGHLANDS PHARMACY LIMITED
BALANCE SHEET
AS AT
30 JUNE 2024
30 June 2024
- 1 -
2024
2023
Notes
£
£
£
£
Fixed assets
Tangible assets
3
12,664
16,338
Current assets
Stocks
57,542
59,422
Debtors
4
207,739
185,153
Cash at bank and in hand
102,499
49,222
367,780
293,797
Creditors: amounts falling due within one year
5
(283,436)
(262,701)
Net current assets
84,344
31,096
Total assets less current liabilities
97,008
47,434
Provisions for liabilities
(3,166)
-
0
Net assets
93,842
47,434
Capital and reserves
Called up share capital
6
50
50
Profit and loss reserves
93,792
47,384
Total equity
93,842
47,434

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 30 June 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 13 June 2025 and are signed on its behalf by:
Mitra Azimi
Director
Company registration number 06521889 (England and Wales)
THE HIGHLANDS PHARMACY LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 JUNE 2024
- 2 -
Share capital
Profit and loss reserves
Total
Notes
£
£
£
Balance at 1 July 2022
50
119,101
119,151
Year ended 30 June 2023:
Loss and total comprehensive income
-
(71,717)
(71,717)
Balance at 30 June 2023
50
47,384
47,434
Year ended 30 June 2024:
Profit and total comprehensive income
-
104,408
104,408
Issue of share capital
6
37
-
37
Dividends
-
(58,000)
(58,000)
Other movements
(37)
-
(37)
Balance at 30 June 2024
50
93,792
93,842
THE HIGHLANDS PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024
- 3 -
1
Accounting policies
Company information

The Highlands Pharmacy Limited is a private company limited by shares incorporated in England and Wales. The registered office is 9 Blenheim Crescent, Luton, LU3 1HA.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings
20% reducing balance
Computers
25% reducing balance
Motor vehicles
25% reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

THE HIGHLANDS PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2024
1
Accounting policies
(Continued)
- 4 -
1.5
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.6
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.7
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future paymen ts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. A m ounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

THE HIGHLANDS PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2024
1
Accounting policies
(Continued)
- 5 -
1.8
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.9
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.10
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.11
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
24
16
THE HIGHLANDS PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2024
- 6 -
3
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 July 2023 and 30 June 2024
161,216
Depreciation and impairment
At 1 July 2023
144,878
Depreciation charged in the year
3,674
At 30 June 2024
148,552
Carrying amount
At 30 June 2024
12,664
At 30 June 2023
16,338
4
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
152,258
149,833
Corporation tax recoverable
-
0
5,160
Amounts owed by group undertakings
2,130
-
0
Other debtors
53,351
30,160
207,739
185,153
5
Creditors: amounts falling due within one year
2024
2023
£
£
Trade creditors
223,701
223,989
Amounts owed to group undertakings
15,099
-
0
Corporation tax
17,536
-
0
Other taxation and social security
2,635
7,067
Other creditors
24,465
31,645
283,436
262,701
THE HIGHLANDS PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2024
- 7 -
6
Called up share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
of £1 each
50
13
50
13
of £1 each
0
8
-
0
8
of £1 each
0
8
-
0
8
of £1 each
0
8
-
0
8
of £1 each
0
5
-
0
5
of £1 each
-
8
-
8
50
50
50
50
7
Parent company

The Parent company is AZ A Pharma Limited by way of its majority shareholding.

2024-06-30 2023-07-01 false false false 13 June 2025 CCH Software CCH Accounts Production 2025.100 No description of principal activity Leda Azimi Mitra Azimi Rohola Azimi Arsalan Baluch 06521889 2023-07-01 2024-06-30 06521889 2024-06-30 06521889 2023-06-30 06521889 core:OtherPropertyPlantEquipment 2024-06-30 06521889 core:OtherPropertyPlantEquipment 2023-06-30 06521889 core:CurrentFinancialInstruments core:WithinOneYear 2024-06-30 06521889 core:CurrentFinancialInstruments core:WithinOneYear 2023-06-30 06521889 core:CurrentFinancialInstruments 2024-06-30 06521889 core:CurrentFinancialInstruments 2023-06-30 06521889 core:ShareCapital 2024-06-30 06521889 core:ShareCapital 2023-06-30 06521889 core:RetainedEarningsAccumulatedLosses 2024-06-30 06521889 core:RetainedEarningsAccumulatedLosses 2023-06-30 06521889 core:ShareCapital 2022-06-30 06521889 core:RetainedEarningsAccumulatedLosses 2022-06-30 06521889 core:ShareCapitalOrdinaryShareClass1 2024-06-30 06521889 core:ShareCapitalOrdinaryShareClass1 2023-06-30 06521889 core:ShareCapitalOrdinaryShareClass2 2024-06-30 06521889 core:ShareCapitalOrdinaryShareClass2 2023-06-30 06521889 core:ShareCapitalOrdinaryShareClass3 2024-06-30 06521889 core:ShareCapitalOrdinaryShareClass3 2023-06-30 06521889 core:ShareCapitalOrdinaryShareClass4 2024-06-30 06521889 core:ShareCapitalOrdinaryShareClass4 2023-06-30 06521889 core:ShareCapitalOrdinaryShareClass5 2024-06-30 06521889 core:ShareCapitalOrdinaryShareClass5 2023-06-30 06521889 core:ShareCapitalOrdinaryShares 2024-06-30 06521889 core:ShareCapitalOrdinaryShares 2023-06-30 06521889 bus:Director2 2023-07-01 2024-06-30 06521889 core:RetainedEarningsAccumulatedLosses 2022-07-01 2023-06-30 06521889 2022-07-01 2023-06-30 06521889 core:RetainedEarningsAccumulatedLosses 2023-07-01 2024-06-30 06521889 core:ShareCapital 2023-07-01 2024-06-30 06521889 core:FurnitureFittings 2023-07-01 2024-06-30 06521889 core:ComputerEquipment 2023-07-01 2024-06-30 06521889 core:MotorVehicles 2023-07-01 2024-06-30 06521889 core:OtherPropertyPlantEquipment 2023-06-30 06521889 core:OtherPropertyPlantEquipment 2023-07-01 2024-06-30 06521889 core:WithinOneYear 2024-06-30 06521889 core:WithinOneYear 2023-06-30 06521889 bus:OrdinaryShareClass1 2023-07-01 2024-06-30 06521889 bus:OrdinaryShareClass2 2023-07-01 2024-06-30 06521889 bus:OrdinaryShareClass3 2023-07-01 2024-06-30 06521889 bus:OrdinaryShareClass5 2023-07-01 2024-06-30 06521889 bus:OrdinaryShareClass4 2023-07-01 2024-06-30 06521889 bus:OrdinaryShareClass1 2024-06-30 06521889 bus:OrdinaryShareClass1 2023-06-30 06521889 bus:OrdinaryShareClass2 2024-06-30 06521889 bus:OrdinaryShareClass2 2023-06-30 06521889 bus:OrdinaryShareClass3 2024-06-30 06521889 bus:OrdinaryShareClass3 2023-06-30 06521889 bus:OrdinaryShareClass4 2024-06-30 06521889 bus:OrdinaryShareClass4 2023-06-30 06521889 bus:OrdinaryShareClass5 2024-06-30 06521889 bus:OrdinaryShareClass5 2023-06-30 06521889 bus:AllOrdinaryShares 2024-06-30 06521889 bus:AllOrdinaryShares 2023-06-30 06521889 bus:PrivateLimitedCompanyLtd 2023-07-01 2024-06-30 06521889 bus:SmallCompaniesRegimeForAccounts 2023-07-01 2024-06-30 06521889 bus:FRS102 2023-07-01 2024-06-30 06521889 bus:AuditExemptWithAccountantsReport 2023-07-01 2024-06-30 06521889 bus:Director1 2023-07-01 2024-06-30 06521889 bus:Director3 2023-07-01 2024-06-30 06521889 bus:Director4 2023-07-01 2024-06-30 06521889 bus:FullAccounts 2023-07-01 2024-06-30 xbrli:pure xbrli:shares iso4217:GBP